Abetis Tablet

About Abetis 10 mg Tablet

Abetis is a tablet that contains Olmesartan Medoxomil 10 mg, a medicine used to treat high blood pressure. It belongs to a group of medicines called angiotensin-II receptor blockers, which help relax blood vessels so the heart does not have to work as hard.

There are 29 brands of Olmesartan Medoxomil listed in Bangladesh. 2 of them have a lower unit price than Abetis. The lowest listed price is Belsar 10 mg Tablet at ৳ 6.00 per unit.

What is Abetis 10 mg Tablet?

Abetis 10 mg is a tablet made by Advanced Chemical Industries PLC that contains the active ingredient Olmesartan Medoxomil. It is used to treat hypertension, which is the medical term for high blood pressure. The medicine works by blocking the action of a natural body chemical called angiotensin-II, which tightens blood vessels. When this chemical is blocked, blood vessels relax and blood pressure can come down. Abetis may be prescribed on its own or alongside other blood pressure medicines. The tablet is available in a pack of 5 x 10.

Uses of Abetis

Abetis is used to treat high blood pressure in adults. It can be taken alone or together with other medicines that lower blood pressure. Lowering blood pressure helps reduce the strain on the heart and blood vessels. Your doctor will decide whether Abetis is suitable for you and whether it should be combined with another medicine. Do not start or stop it without medical advice.

How to use Abetis

Take Abetis exactly as your doctor tells you. The doctor decides the dose and how long you take it, and this may be adjusted over time based on your blood pressure readings. Swallow the tablet as directed. Food does not affect how the body absorbs this medicine. Do not change the dose yourself. If you miss a dose, ask your doctor or pharmacist what to do rather than doubling up.

Side effects of Abetis

Some people may notice side effects such as back pain, headache, diarrhoea, bronchitis, flu-like symptoms, sore throat, a runny nose, or sinus problems. Changes in some blood test results have also been reported. Less common effects include chest pain, swelling of the ankles or feet, and joint pain. Tell your doctor if any side effect bothers you or does not go away, and seek medical help for severe or worrying symptoms.

Safety and precautions

Tell your doctor if you are allergic to Olmesartan or any part of this tablet. This medicine should not be used during pregnancy; if pregnancy is suspected or confirmed, contact your doctor straight away, as drugs acting on this system can harm the developing baby. It is not known whether Olmesartan passes into breast milk, so discuss feeding with your doctor. People with kidney problems, heart failure or liver problems should speak to their doctor before starting. Ask your doctor or pharmacist about interactions with other medicines you take.

Frequently asked questions

What does the tablet form and 10 mg strength mean?

Abetis comes as a tablet to be swallowed, and 10 mg is the amount of Olmesartan Medoxomil in each tablet. The doctor chooses the strength that suits you and decides how it should be taken. Do not change the strength or schedule on your own.

What is Abetis used for and what kind of medicine is it?

Abetis is used to treat high blood pressure and may be taken alone or with other blood pressure medicines. It is an angiotensin-II receptor blocker, which works by blocking a body chemical that narrows blood vessels, helping them relax.

What side effects should I watch for and when should I call the doctor?

Watch for back pain, headache, diarrhoea, flu-like symptoms, sore throat or a runny nose, and less common effects like ankle swelling or joint pain. Call your doctor if side effects are severe, persistent or worrying, or if you feel unwell.

What is the price of Abetis?

The listed price is ৳ 7.00.

Indications

Abetis tablet is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Pharmacology

Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, Kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in vascular smooth muscle. An AT 2 receptor is found also in many tissues, but this receptor is not known to be associated with cardiovascular homeostasis. Olmesartan has more than a 12,500-fold greater affinity for the AT 1 receptor than for the AT 2 receptor. Olmesartan medoxomil does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II levels do not overcome the effect of olmesartan on blood pressure.

Dosage & Administration

Dosage must be individualized. The usual recommended starting dose of Olmesartan is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not appear to have a greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.

No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal impairment (creatinine clearance <40 ml/min) or with moderate to marked hepatic dysfunction. For patients with possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal function), Olmesartan should be initiated under close medical supervision and consideration should be given to use of a lower starting dose. Olmesartan may be administered with or without food.

Paediatric use: Safety and effectiveness in paediatric patients have not been established.

Interaction

No significant drug interactions were reported in studies in which Abetis was co-administered with digoxin or warfarin in healthy volunteers. The bioavailability of olmesartan was not significantly altered by the co-administration of antacids. Abetis is not metabolized by the cytochrome P450 system and has no effects on P450 enzymes; thus, interactions with drugs that inhibit, induce, or are metabolized by those enzymes are not expected. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) including selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) in patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including Abetis, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving Abetis and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including Abetis may be attenuated by NSAIDs including selective COX-2 inhibitors.

Contraindications

Olmesartan is contraindicated in patients who are hypersensitive to any component of this product.

Side Effects

Abetis has been evaluated for safety in more than 3825 patients/subjects, including more than 3275 patients treated for hypertension in controlled trials. Treatment with Abetis was well tolerated, with an incidence of adverse reactions similar to placebo. The overall frequency of adverse reactions was not dose related. Analysis of gender, age and race groups demonstrated no differences between Abetis and placebo treated patients. The rate of withdrawals due to adverse reactions in all trials of hypertensive patients was 2.4% of patients treated with Abetis and 2.7% of control patients. In placebo controlled trials, the only adverse reaction that occurred in more than 1% of patients treated with Abetis and at a higher incidence versus placebo was dizziness (3% vs. 1%)

The following adverse reactions occurred in placebo-controlled clinical trials at an incidence of more than 1% of patients treated with Abetis, but also occurred at about the same or greater incidence in patients receiving placebo: back pain, bronchitis, creatine phosphokinase increased, diarrhea, headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis and sinusitis. The incidence of cough was similar in placebo (0.7%) and Abetis (0.9%) patients.

Pregnancy & Lactation

When pregnancy is detected, discontinue this product as soon as possible. When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. It is not known whether Olmesartan is excreted in human milk, but Olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Precautions & Warnings

As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with Abetis. In patients whose renal function may depend upon the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. Similar results may be anticipated in patients treated with Abetis.

Overdose Effects

There is no experience of overdose with Abetis. The most likely effects of Abetis overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurred. If intake is recent, gastric lavage or induction of emesis may be considered. Clinically significant hypotension due to an overdose of Abetis requires the active support of the cardiovascular system, including close monitoring of heart and lung function, the elevation of the extremities, and attention to circulating fluid volume and urine output.

Storage Conditions

Store in cool & dry place below 30ºC, protect from light & moisture. Keep out of the reach of children.

Alternative brands of Olmesartan Medoxomil

Other brands with the same generic name, cheapest first.

See all 29 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.